Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 
WhatsApp Image 2020-08-30 at 10.58.51 PM

The Center for Advanced-Applied Biological Sciences &
Entrepreneurship-Journal (TCABSE-J)

The special inaugural issue of TCABSE-J launched on October 25th, 2020!

  • TCABSE-J Perspective:

    • Combination of anti-asthmatics with remdesivir may reduce the necessity for
      the usage of ventilators in severe COVID-19 cases including the elderly.​

             (Yedidi 2020) 

ISSN: 2583-2557

CCLicense_edited.jpg
  • TCABSE-J Applications Report:

    • Triplet codons to amino acids: Applications of machine learning approaches to protein translation made simple for college students. (Koppala et al. 2020)

  • TCABSE-J Commentary:

    • Genome packing: the complicated complexity! (Yedidi 2020)

  • TCABSE-J Structure Report:

    • X-ray crystal structure analysis of a multidrug-resistant variant of HIV-1 protease in complex with a chroman-4-amine containing protease inhibitor. (Yedidi 2020)

  • TCABSE-J Communications:

    • Vantage point: new insights into old enteric fever treatment by rescuing the host cell ubiquitin-proteasome system. (Dadala et al. 2020)

  • TCABSE-J Review:

    • Impact of COVID-19 on culture and society. (Addala & Yedidi 2020)

  • TCABSE-J Strategic Communications:

    • CRISPR/Cas9 mediated intervention to target the host CD4+ T cells that are latently infected with HIV-1 genome. (Ramavarapu & Yedidi 2020)

  • TCABSE-J Strategic Communications:

    • The OMICAS, Can-IT: Onco-Molecular Immunotherapeutic Constellation Analytics Spectrum in Cancer Immunotherapy. (Aggunna & Yedidi 2020)

  • TCABSE-J Analysis Report:

    • Mapping and analysis of cathepsin cleavage site distribution on the 3-D model
      of human thyroglobulin for potential inhibitor design. (Gandi & Yedidi 2020)

  • TCABSE-J Applications Report:

    • Leveraging the active site steric hindrance for GTP hydrolysis in mutant
      K-Ras variants to achieve selectivity in kinase inhibitors for cervical cancer. (Chittipeddi et al. 2020)

Please contact us at tcabsej@gmail.com with any questions!